Ramana Hechhu, Rangapuram Vasanthi, Tamrat Balcha Balla, Kaliaperumal J
email@example.com , firstname.lastname@example.org
Ramana Hechhu1, Rangapuram Vasanthi2*, Tamrat Balcha Balla1, Kaliaperumal J1
1School of Pharmacy, College of Health Sciences and Medicine, Wolaita Sodo University, Ethiopia.
2GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad, Telangana State, India.
Volume - 15,
Issue - 4,
Year - 2022
World Health Organization (WHO) has assessed that coronavirus disease 2019 (COVID-19) as an epidemic. However, an effective antiviral for COVID-19 is still uncertain. Since the onset of the outbreak, the scientific and clinical community keep proposing many agents that would have efficacy against COVID-19. Arbidol is an indole core with proven effectiveness against influenza over the past few years apart from critics. The concrete hypothesis of arbidol interaction with spike glycoprotein prevents the entry of virus. Further, demonstrated clinical efficiency of arbidol against RNA virus and broad-spectrum inhibition of influenza A and B virus, adenovirus, and other viruses, including hepatitis C virus, drives us to seek more understating of the molecule and its clinical possibilities. In this review, we attempt to describe the many possible hypotheses of arbidol against Covid-19.
Cite this article:
Ramana Hechhu, Rangapuram Vasanthi, Tamrat Balcha Balla, Kaliaperumal J. Current clinical anticipation of Arbidol against COVID-19: Possibilities. Research Journal of Pharmacy and Technology. 2022; 15(4):1653-8. doi: 10.52711/0974-360X.2022.00276
Ramana Hechhu, Rangapuram Vasanthi, Tamrat Balcha Balla, Kaliaperumal J. Current clinical anticipation of Arbidol against COVID-19: Possibilities. Research Journal of Pharmacy and Technology. 2022; 15(4):1653-8. doi: 10.52711/0974-360X.2022.00276 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-4-42
1. Yung-Fang Tu et al., A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int. J. Mol. Sci. 2020; (21): 2657.
2. Mayur S. Jain and Shashikant D. Barhate. Corona viruses are a family of viruses that range from the common cold to MERS corona virus: A Review. Asian J. Res. Pharm. Sci. 2020; 10 (3): 204-210.
3. Naresh BV. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic, Asian J. Pharm. Res. 2020; 10 (3): 233-238.
4. Prathmesh L. Jarag et al., On overview- Corona virus and Hanta virus Disease, Asian J. Res. Pharm. Sci. 2020; 10 (3):178-182.
5. Akshay Gade et al., SARS-Cov-2 The Beta Genome Coronavirus: A Brief Overview, Pathogenesis and Treatment. Asian J. Res. Pharm. Sci. 2020; 10 (4): 299-310.
6. Vandna Dewangan et al., The Exploring of Current Development status and the unusual Symptoms of Coronavirus Pandemic (Covid-19). Res. J. Pharmacology and Pharmacodynamics.2020; 12 (4):172-176.
7. Manisha Rokade and Pradnya Khandagale. Coronavirus Disease: A Review of a New Threat to Public Health, Asian J. Pharm. Res. 2020; 10(3):241-244.
8. Ritika Gupta. The Management of Coronavirus Pandemic 2019-2020, Asian J. Pharm. Res. 2020; 10(4):327-330.
9. Akshay R. Yadav and Shrinivas K. Mohite. A Review on Severe Acute Respiratory Infection (SARI) and its Clinical Management in Suspect/ Confirmed Novel Coronavirus (nCoV) Cases Res. J. Pharma. Dosage Forms and Tech. 2020; 12(3):178-180.
10. Coronavirus disease 2019 (COVID-19) Situation Report. World Health Organization. Available from: URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
11. Samir Derouiche. Current Review on Herbal Pharmaceutical improve immune responses against COVID-19 infection. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(3):181-184.
12. Sindhu. T. J et al., Elizabeth Wilson, Antiviral screening of Clerodol derivatives as COV 2 main protease inhibitor in Novel Corona Virus Disease: In silico approaches. Asian J. Pharm. Tech. 2020; 10(2):60-64.
13. Akshay R. Yadav and Shrinivas K. Mohite. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(3):227-230.
14. Khamitov RA et al., Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008; (53): 9–13.
15. Kramarev SA and Moshchich AP. The treatment of influenza and acute respiratory viral infections. Lik Sprava. 2013; 99–106.
16. Dong L et al., Clinical course and risk factors for mortality of adult inpatients with COVID 19 in Wuhan, China: a retrospective cohort study. Lancet. published online 2020; Mar 11.
17. Glushkov R. Arbidol. Drugs Future. 1992; (17):1079–81.
18. Guskova T and Glushkov R. Efficacy and safety of arbidol in treating and prophylaxis of influenza: clinical trials. In: Glushkov R, editor. Arbidol—a new antiviral, immunomodulator, interferon inducer (Russian). Moscow: Timotek; 1999; 63–76.
19. Boriskin Y et al., Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008; (15): 997–1005.
20. Delogu I et al., In vitro antiviral activity of arbidol against chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 2011; (90): 99–107.
21. Blaising J et al., Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; (107): 84–94.
22. Leneva IA et al., Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009; (81):132–40.
23. Leneva IA et al., Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A (Russian). Ter Arkh. 2005; (77): 84–8.
24. Leneva I et al., Study of antiviral activity of Russian domestic anti-influenza agents in cell culture and in animal model. Vopr Virus (Russian). 2010; (3):19–27.
25. Brooks MJ et al., Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol. 2012; (84):170–81.
26. Burtseva E et al., The specific features of the cocirculation of influenza viruses in the 2010- 2011 postpandemic period according to the results of activities of the D. I. Ivanovsky Research Institute of Virology, Ministry of Health and Social Development of Russia (Russian). Vopr Virus. 2012; (57): 20–8.
27. Sominina A et al., Influenza surveillance in Russia based on epidemiological and laboratory data for the period from 2005 to 2012. Am J Infect Dis. 2013; (9): 77–93.
28. Pécheur E-I et al., The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol. 2016; 90(6): 3086– 92.
29. Canrong Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B. 2020;10(5): 766-788.
30. Lisi Deng et al., Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study, Journal of Infection. 2020; (81): 1–5.
31. Chang Chen et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv preprint, this version posted 2020; March 20.
32. Elena V. Proskurnina et al., Antioxidant Potential of Antiviral Drug Umifenovir, Molecules. 2020; (25): 1577.
33. Zhen Zhu et al., Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19, Journal of Infection. 2020; (81): 21–23.
34. Tobaiqy M et al., Therapeutic management of patients with COVID-19: a systematic review, Infection Prevention in Practice. 2020; (2) 100061.
35. Naveen Vankadari. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein, International Journal of Antimicrobial Agents. xxx(xxxx)xxx, JID:ANTAGE [m5G;,2020;(4) May13:56.
36. Qibin Liu et al., The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan, medRxiv preprint, this version posted 2020; April 17.
37. Lian N et al., Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study, Clinical Microbiology and Infection. (2020); (26): 917-921.
38. Xi Wang et al., The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro, Cell Discovery.2020; (6): 28.
39. Renyi Wu et al., An Update on Current Therapeutic Drugs Treating COVID-19, Current Pharmacology Reports, published online 2020; May11.
40. Villalaín J. Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. J Phys Chem B. 2010;114(25):8544–54.
41. Leneva IA et al., Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antivir Res. 2009;81(2):132–40.
42. James M. Sanders et al., Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review, Clinical Review & Education, JAMA. 2020;323(18):1824-1836.
43. Ping Xu et al., Arbidol/IFN-a2b therapy for patients with corona virus disease 2019: a retrospective multicentre cohort study, Microbes and Infection.2020; (22): 200-205.
44. Juan A. Siordia Jr et al., Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials, SN Comprehensive Clinical Medicine.2020; (2):1120–1131.
45. Hui Huang et al., Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study, Research square, Pulmonology, (Preprint: Please note that this article has not completed peer review). DOI: 10.21203/rs.3.rs-24667/v1.
46. Jinnong ZhANG et al., Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission-preliminary report of a retrospective case-control study, chinaXiv:202002.00065v1.
47. Mishra PR et al., Covid-19-drug-candidate-umifenovir-secures-dcgi-approval-phase-iii-clinical-trial. Available from: URL: https://www.csir.res.in/slider/ csir-cdri’s